The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35345249/
Sodium-glucose co-transporter (SGLT)-2 inhibitors were initially developed for management of type 2 diabetes but have been shown to offer improved outcomes in heart failure, a condition in which concomitant chronic...
Relevance: In this review we discuss in detail the evidence for SGLT2 inhibitors in heart failure, particularly with regard to kidney health.
Share
Conclusions: Initiation of empagliflozin in patients hospitalized for AHF produced clinical benefit regardless of the degree of symptomatic impairment at baseline; and improved symptoms, physical limitations and quality of life, with benefits seen as early as 15 days and maintained through 90 days.
Share
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35413307/
Heart failure (HF) is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and associated with elevated natriuretic peptide levels and/or objective evidence...
Conclusion: This review focuses the recent advances in the pharmacological agents for treatment of chronic heart failure, including their mechanisms of action, the evidence based on the clinical trials, and the guideline recommendations for their use.
Share
Conclusion/Relevance: Empagliflozin now has FDA approval for reducing cardiovascular death or hospitalization among patients with heart failure with preserved left ventricular ejection fraction, defined as more than 40%, with or without diabetes.
Share
Mode of Action and Human Relevance Assessment of Male CD-1 Mouse Renal Adenocarcinoma Associated With Lifetime Exposure to Empagliflozin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35393688/
Inhibition of sodium-glucose cotransporter-2 (SGLT2) has been shown to be a safe and efficacious approach to support managing Type 2 diabetes. In the 2-year carcinogenicity study with the SGLT2 inhibitor...
Conclusions and Implications: Considering that empagliflozin is not genotoxic in the standard battery of genotoxicity tests, and not all five key events are present in the context of female mice, rats or humans, nor for other osmotic diuretics or other SGLT2 inhibitors, the observed male mouse renal tumors are not considered relevant to humans.
Share